Pediatrix Medical Group (MD) to Release Quarterly Earnings on Thursday

Pediatrix Medical Group (NYSE:MD) is expected to post its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.53 per share and revenue of $486.23 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 9:00 AM ET.

Pediatrix Medical Group Price Performance

MD stock opened at $21.50 on Thursday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average price of $21.72 and a 200 day moving average price of $19.19. Pediatrix Medical Group has a 12 month low of $11.84 and a 12 month high of $24.99. The stock has a market cap of $1.85 billion, a PE ratio of 11.32 and a beta of 0.76.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MD shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Finally, Truist Financial upped their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.00.

Insider Transactions at Pediatrix Medical Group

In other news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael A. Rucker sold 10,478 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $23.00, for a total value of $240,994.00. Following the completion of the sale, the director directly owned 59,101 shares in the company, valued at $1,359,323. This represents a 15.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in shares of Pediatrix Medical Group by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 3,399,778 shares of the company’s stock worth $56,942,000 after buying an additional 81,554 shares during the period. Geode Capital Management LLC lifted its position in Pediatrix Medical Group by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock valued at $46,674,000 after purchasing an additional 14,421 shares during the period. Boston Partners lifted its holdings in Pediatrix Medical Group by 0.6% in the third quarter. Boston Partners now owns 1,427,953 shares of the company’s stock valued at $24,063,000 after acquiring an additional 8,335 shares during the period. Qube Research & Technologies Ltd boosted its stake in shares of Pediatrix Medical Group by 55.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock worth $19,150,000 after acquiring an additional 407,780 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Pediatrix Medical Group by 47.6% during the 3rd quarter. Invesco Ltd. now owns 877,019 shares of the company’s stock valued at $14,690,000 after acquiring an additional 282,840 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.